A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection
Cell Reports Medicine, January 2, 2026
3
January, 2026
23
October, 2025
Hydrogen sulfide to modulate Glycated hemoglobin and gut microbiome in type 2 diabetes mellitus
Metabolism Open, Volume 28, 2025
12
May, 2025
Procalcitonin-guided early cessation of antibiotics prevents gut inflammation and preserves gut microbiome: Data from the PROGRESS controlled trial
Evdoxia Kyriazopoulou, Emmanouil Stylianakis, Georgia Damoraki, Panagiotis Koufargyris, Ioannis Kollias, Konstantina Katrini, Elina Drakou, Konstantinos Marousis, Andronikos Spyrou, Styliani Symbardi, Nikolaos Alexiou, Zoi Alexiou, Malvina Lada, Garyfallia Poulakou, Georgios Chrysos, George Adamis, Evangelos J. Giamarellos-Bourboulis Int J Antimicrob Agents. 2025 Apr 9:107507 DOI: 10.1016/j.ijantimicag.2025.107507 View article 🡆 FundingHellenic Institute for the Study of Sepsis
1
October, 2015
SPECIFY
Completed study Official Study Title Scoring PErsonalized needs in Clostridium difficile Infections for Fidaxomixin therapY Brief Description The SPECIFY study is a non-interventional study aiming to develop a complex score composed by clinical data, genomic data and protein biomarkers to early predict patients with infection by Clostridium difficile at high likelihood to develop organ